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Abstract
Background: Previous meta-analyses of treatments for Bell’s palsy are still inconclusive due to different
comparators, insufficient data, and lack of power. We therefore conducted a network meta-analysis combining
direct and indirect comparisons for assessing efficacy of steroids and antiviral treatment (AVT) at 3 and 6 months.
Methods: We searched Medline and EMBASE until September 2010 using PubMed and Elsviere search engines.
A network meta-analysis was performed to assess disease recovery using a mixed effects hierarchical model.
Goodness of fit of the model was assessed, and the pooled odds ratio (OR) and 95% confidence interval (CI) were
estimated.
Results: Six studies (total n = 1805)were eligible and contributed to the network meta-analysis. The pooled ORs for
resolution at 3 months were 1.24 (95% CI: 0.79 - 1.94) for Acyclovir plus Prednisolone and 1.02 (95% CI: 0.73 - 1.42)
for Valacyclovir plus Prednisolone, versus Prednisolone alone. Either Acyclovir or Valacyclovir singly had significantly
lower efficacy than Prednisolone alone, i.e., ORs were 0·44 (95% CI: 0·28 - 0·68) and 0·60 (95% CI: 0·42 - 0·87),
respectively. Neither of the antiviral agents was significantly different compared with placebo, with a pooled OR of
1·25 (95% CI: 0·78 - 1·98) for Acyclovir and 0·91 (95% CI: 0·63 - 1·31) for Valacyclovir. Overall, Prednisolone-based
treatment increased the chance of recovery 2-fold (95% CI: 1·55 - 2·42) compared to non-Prednisolone-based
treatment. To gain 1 extra recovery, 6 and 26 patients need to be treated with Acyclovir and prednisolone
compared to placebo and prednisolone alone, respectively.
Conclusions: Our evidence suggests that the current practice of treating Bell’s palsy with AVT plus corticosteroid
may lead to slightly higher recovery rates compared to treating with prednisone alone but this does not quite
reach statistical significance; prednisone remains the best evidence-based treatment.
Background
Bell’s palsy is a condition characterized by an acute
onset of facial nerve palsy with no known cause. The
incidence is about 20/year/100,000 population [1], and
leads to a considerable disturbance in social activities
among patients[2].
Although the actual cause of Bell’sp a l s yi su n k n o w n ,
the widely accepted mechanism is inflammation of the
facial nerve during its course through the bony labyr-
inthine part of the facial canal, which leads to compres-
sion and demyelination of the axons, and disruption of
blood supply to the nerve itself[3]. Previous studies have
suggested viral infection as the etiology of the disease
based on serological evidence;[4,5] for example, positive
serology for Herpes Simplex virus (HSV) has been
reported in 20-79% of patients.
Treatment of Bell’s palsy varies, and no clear consensus
exists. Most physicians prescribe corticosteroids as a pri-
mary treatment due to its potential to reduce swelling
and inflammation. The addition of antiviral treatment
(AVT) such as Acyclovir or Valacyclovir is aimed at era-
dication of HSV infection. Acyclovir, a nucleoside analog,
inhibits HSV replication through inhibition of viral DNA
polymerase. It is absorbed slowly from the gastrointest-
inal tract, necessitating the use of a five-times daily regi-
men. Valacyclovir, a Valine derivative of Acyclovir, is
claimed to lead to higher drug levels through conversion
to Acyclovir by intestinal and hepatic esterase enzymes,
leading to less intensive regimens. Its distribution,
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identical to Acyclovir[6].
Efficacy of AVT in Bell’s palsy is still not established,
and the question exists whether adding AVT to another
treatment such as corticosteroid can lead to better and
faster recovery compared with corticosteroids alone or
without treatment. The original Cochrane systematic
review of this topic[7] included 3 studies; these were
heterogeneous however and could not be pooled. Since
that date, there have been at least 3 more large indivi-
dual studies[8-13] and 3 more recent meta-analyses
[14-16] published, although the comparator groups vary
considerably and make traditional direct meta-analysis
difficult. The meta-analsis by de Almeida et al. applied
logistic regression analysis to assess interation effects
between corticosteroids and AVT, however this does
not account for heterogeneity and did not estimate the
individual effect of AVT(Acyclovir or Valacyclovir).
Furthermore, the review combined adult and paediatric
studies (6 studies), in which dosages and effects of treat-
ments may be different. The most recent update of the
Cochrane systematic review included 6 studies [17], but
did not look at the effects of AVTs alone. We therefore
conducted a systematic review and network meta-
analysis with the aim of comparing complete recovery
rates at 3 and 6 months for corticosteroids, AVT
(Acyclovir or Valacyclovir), or the combination of both
for treatment of adult Bell’s palsy. Performing a network
meta-analysis by borrowing information from indirect
comparisons integrates information about relative treat-
ment efficacy[18-20]. This technique has been applied in
systematic reviews of other clinical topics such as
chronic insomnia[21], polymer-based drug-eluting stents
[22], and highly-active AVT[23].
Methods
Search strategy
One author (NP) located studies in MEDLINE (from
1966 to August 2010) and EMBASE (from 1950 to Sep-
tember 2010) using PubMed and Ovid search engines.
Search terms used were as follows: (Bell’s palsy or idio-
pathic facial palsy) and (antiviral agents or acyclovir or
valacyclovir), limited to randomized controlled trials.
Search strategies for both databases are described in the
additional file 1.
Selection of study and inclusion/exclusion criteria
Abstracts and/or full papers of identified studies were
reviewed by one author (NP) and checked by another
author (TA). Studies were included if they were RCTs,
and studied subjects aged 18 years or older with suffi-
cient data. Non-English papers were excluded from the
review. Where eligible papers had insufficient informa-
tion, corresponding authors were contacted by e-mail
for additional information. The reference lists of the
retrieved papers were also reviewed to identify relevant
publications. Where there were multiple publications
from the same study group, the most complete and
recent results were used.
Data extraction & Quality assessment (QA)
Data extraction was independently performed in dupli-
cate by PN and AT using a standardized data extraction
form, which included study design, sample size, patient
characteristics (i.e., age, gender), type of intervention
and comparator, outcomes, and follow-up time. Any dis-
agreement was resolved by discussion.
Quality of studies was also independently assessed by
PN and AT based on a modified Jadad score which
takes into account randomization technique, allocation
concealment, blinding, intention to treat, and patient
attrition[24]. Each item was graded 2, 1, or 0 for appro-
priately, partially, and inappropriately described meth-
ods. Any disagreement between the two reviewers was
discussed and resolved by consensus.
Outcome
Complete recovery was defined as a score ≤2o nt h e
House-Brackman Facial Recovery scale[12,13,25], ≥ 8o n
the Facial Palsy Recovery Index[8], > 36 points on
theYanagihara score[10], or 100 on the Sunnybrook
scale[9].
Statistical analysis
For direct meta-analysis, the odds ratio (OR) and var-
iance of each study were estimated and pooled. Hetero-
geneity of ORs was assessed using Cochran’s Q test and
I
2. If heterogeneity was present, ORs were pooled using
the random effects model, i.e. Der-Simonian and Laird
method. Meta-regression wasa p p l i e dt oa s s e s sw h e t h e r
age, gender, and QA were sources of heterogeneity, if
these data were available. Contour enhanced funnel
plots were used to detect publication bias due to small
study effects [26-29]. Trim and fill meta-analysis was
applied to impute the number of missing studies [30].
For network meta-analysis, treatment groups were
considered in a mixed effects hierarchical model with
logit link function using the xtmelogit command in
STATA[31]. The treatments were included in the model
as fixed effects whereas the study was included as a ran-
dom effect. Likelihood estimates were used for estima-
tion of parameters in the model. Goodness of fit of the
model was assessed using the Hosmer-Lemeshow Chi-
square test. The pooled ORs and 95% confidence inter-
vals (CI) were estimated by exponential coefficients of
treatments. Discrepancy of treatment effects between
direct and indirect meta-results was then assessed using
the standardized normal method (Z), i.e. by dividing the
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to treat/harm (NNT/NNH) was estimated using prob-
ability of complete recovery and ORs derived from the
mixed effects hierarchical model, where the ORs were
converted to risk ratios following the method of
Zhang et al[33]. All analyses were performed using
STATA version 11.0. P values < 0·05 were considered as
statistically significant except for the heterogeneity test
where <0·10 was used.
Results
A flow diagram of study selection is shown in Figure 1.
Fourteen and twenty-five studies were identified from
MEDLINE and EMBASE databases, respectively. Among
these 39 studies, 1 studies were duplicates, 13 studies
were ineligible, leaving 12 studies to review. Six studies
were excluded; two were in Spanish, one was in German,
and 3 were subsets or duplicated reports, leaving six stu-
dies[8-10,12,13,25] with a total of 1805 patients for analy-
sis. Characteristics of the 6 included studies are described
in table 1. Five studies[8-10,12,13] compared recovery
rates of AVT plus corticosteroid with corticosteroid
alone or placebo; the remaining study directly compared
the recovery rate of AVT against corticosteroid[25]. Two
studies were based on factorial design[9,12] and the
others were parallel randomized control trials. The AVTs
used were Acyclovir for 4 studies[8,12,13,25] and Valacy-
clovir for the other 2 studies[9,10]. Prednisolone was the
major corticosteroid used. Mean age of participants in
these studies ranged from 40 to 50 years, and percentage
of male participants ranged from 45% to 59%. Median
quality assessment score was 8 (range = 2-12).
14 articles identified from 
MEDLINE
14 excluded:
- 6 duplicates 
- 5 duplicated reports/or 
commentaries
- 2 systematic reviews 
- 1 narrative review
14 eligible for review
6 included in the review
14 articles identified from 
EMBASE
8 excluded:
- 2 Spanish papers 
- 6 subsets or 
duplicated reports
Figure 1 Diagram of selection of studies.
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Among 6 studies, 3 studies[8,12,13] compared recovery
rates within 3 months between Acyclovir plus Prednisolone
versus Prednisolone alone (table 2). Pooled treatment
effects were heterogeneous (Chi-sqaure = 6·30 (d.f. = 2)
p = 0·043; I
2= 68.3%). Using the random effects model gave
a pooled OR of 1·39 (95% CI: = 0·52 - 3·75), i.e. patients
who received Acyclovir plus Prednisolone were about 40%
more likely to recover within 3 month than patients who
received Prednisolone alone, although this did not reach
statistical significance. Only 2 studies[9,10] compared
recovery rates between Valacyclovir plus Prednisolone and
Prednisolone. They were homogeneous and the pooled OR
with fixed effect model was 1·17 (95% CI: 0·75 - 1·81).
Combining 5 studies[8-10,12,13] to assess the effect of
AVT (Acyclovir/Valacyclovir) plus Prednisolone versus
Prednisolone found moderate heterogeneity (Chi-sqaure =
7.78 (d.f. = 4) p = 0.100; I
2 = 48.6%). The pooled OR with
Table 1 Baseline characteristics of included studies
Author
(Year)
N Mean
age
% Male
Participants
Mean
disease
severity
score
Type of treatment Outcomes FU time
(month)
QA
score
Intervention (dosage) Control
Adour
et al.
(1996) [8]
99 43 50 3 (FPRP) Acyclovir 2,000 mg/day × 10 days
Prednisolone 30 mg/kg/day × 5 days,
10 mg/day × next 5 days
Prednisolone
with the same
dosage
FPRI ≥ 84 7
De Diego
et al.
(1998)[25]
101 - - - Acyclovir 2,400 mg/day ×10 days Prednisolone 1
mg/kg/day ×
10 days, taper
over next 6
days
HB grade ≤ II,
FPRI score≥ 8
33
Hato et al.
(2007)[10]
221 50 53 15
(Yanagihara)
Valacyclovir 1,000 mg/day × 5 days
Prednisolone 60 mg/day for 5 days,
taper with Mecobalamin 1·5 mg/day ×
6 months
Placebo Yanagihara score
> 36 points, no
facial contracture
or synkinesis
69
Sullivan et
al. (2007)
[12]
551 44 51 3.6 (HB) Acyclovir 2000 mg/day × 10 days
Prednisolone 50 mg/day × 10 days
Placebo HB grade I 3, 9 12
Yeo et al.
(2008)[13]
91 41 45 3.7 (HB) Acyclovir 2,400 mg/day × 5 days
Prednisolone 1 mg/kg/day × 4 days
with maximum of 80 mg/day, 60 mg/
day × 5-6 day, 40 mg/day × 7-8 day,
20 mg/day × 9-10 day
Placebo HB grade ≤ II 2, 6 2
Engstrom
et al.
(2008) [9]
829 40 59 4 by HB Valacyclovir 3,000 mg/day × 7 days
Prednisolone 60 mg/day × 5 days, 10
mg/day until 10 days
Placebo Sunnybrook 100/
100, HB ≤ II
1, 2, 3,
6, 12
12
Table 2 Describe numbers of recovery according to treatment groups for each included study
Author Treatment groups Recovery at 3 months Total N Recovery after 3 months Total N
Adour et al. [8] Acy+Pred 34 38 49 53
Pred 20 29 35 46
De Diego[25] Acy 42 54 - -
Pred 44 47 - -
Engstorm et al. [9] Val+Pred 134 206 149 206
Val 113 207 120 207
Pred 137 210 150 210
Plac 111 206 127 206
Hato et al. [10] Val+Pred 94 114 110 114
Pred 80 107 96 107
Sullivan et al. [12] Acy+Pred 99 124 115 124
Acy 76 123 96 123
Pred 109 127 122 127
Plac 79 122 104 122
Yeo et al. [13] Acy + Pred 36 44 41 44
Pred 35 47 40 47
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i.e. AVT plus Prednisolone had 21% higher chance of
complete recovery than Prednisolone alone but this
was non-significant. Meta-regression suggested that
quality assessment score and disease severity at base-
line might be a source of heterogeneity, reducing I
2
from 48.6% to 32.5% and 15.5% respectively although
both variables were non-significantly associated with
treatment effects. Pooling studies with quality assess-
ment scores > 8 (median) suggested no benefit of AVT
plus Prednisolone compared with Prednisolone alone
(pooled OR = 1.01, 95% CI: 0.74 - 1.37). Two studies
[8,10] had more severe patients at baseline (i.e., mean
scores were 3 by facial palsy recovery index and 15 by
Yanagihara score) compared with the other 3 studies
[9,12,13] (i.e., mean scores were 3.6 to 4 by HB), see
table 1. Pooling within the severe group only suggested
the possibility of a treatment effect but this was non-
significant (OR = 2.04, 95% CI: 0.93 - 4.46) while treat-
ment effect was close to the null in the less severe
group (OR = 0.94, 95%CI: 0.66 - 1.33). Contour
enhanced funnel plots suggested asymmetry, i.e., four
studies lay in the non-sigificant area (white, p > 5%)
but the study with the largest treatment effect and SE
lay in the positive-moderate significant area (1% ≤ p ≤
5%, see Figure 2), suggesting that the asymmetry might
be due to missing, non-significant studies. “metatrim”
analysis indicated that only one negative study with
borderline significance was missing; adjusting for this
presumed missing studies resulted in an ORof 1.08
(95% CI: 0.66 - 1.76).
Three studies[8,12,13] reported the recovery rate
between direct comparisons of Acyclovir plus Predniso-
lone versus Prednisolone after receiving treatments at 4
to 9 months (table 2). Treatment effects were statistically
heterogeneous (Chi-square = 6·07 (d.f. = 2), p = 0·048;
I2 = 67·0%), and the random effects pooled OR was
1·63 (95% CI: 0·47 - 5·75). Pooling effects of Valacyclovir
plus Prednisolone versus Prednisolone was performed
based on only 2 heterogeneous studies[9,10]. The
random effects pooled OR was 1·58 (95% CI: 0·55 - 4·48).
There was only 1 study each that compared Acyclovir
[12] or Valacyclovir[9] alone versus Prednisolone and
this was insufficient for pooling.
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Figure 2 Contour enhanced funnel plot: AT plus Prednisolone versus Prednisolone.
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All six studies[8-10,12,13,25] were able to contribute to
a network meta-analysis, for a total of 1,805 patients, as
described in table 2. Overall, 177 (9·8%), 207 (11·5%),
567 (31·4%), and 328 (18·2%) received only Acyclovir,
Valacyclovir, Prednisolone, or placebo whereas 206
(11·4%) and 320 (17·7%) received Acyclovir plus Predni-
solone and Valacyclovir plus Prednisolone, respectively.
One-thousand two-hundred and forty-three patients had
complete recovery (68·9%) within three months.
All treatment comparisons and results of the network
meta-analysis for 3 month outcomes are displayed in
Figure 3a. Each line in the figure represents a rando-
mized comparison, in which the head and the tail of
that line refer to intervention and reference groups
respectively. Figures on the lines refer to estimated
indirect ORs for that comparison; ORs less than one
indicate that the intervention group had lower recovery
than the reference group, whereas ORs higher than one
mean that the intervention group had higher recovery
than the reference group. The mixed-effects model with
a random intercept and a constant slope was applied to
assess treatment effects. The estimated variance between
studies was 0·17 (95% CI: 0·04 - 0·76). Hosmer-
Lemeshow test found that the model was a good fit
(Chi-square = 12·99, p = 0·072).
Treatment effects for all comparisons are shown in Fig-
u r e3 aa n dt a b l e3 .A d d i n gA c y c l o v i ro rV a l a c y c l o v i rt o
Prednisolone did not significantly increase recovery rate
when compared with Prednisolone alone, although the
point estimates suggest a potential benefit of the combi-
nation, i.e., ORs were 1·24 (95% CI: 0·79 - 1·94) and 1·02
(95% CI: 0·73 - 1·42) for Acyclovir and Valacyclovir,
respectively. For monotherapy, either Acyclovir (OR =
0·44, 95% CI: 0·28 - 0·68) or Valacyclovir (OR = 0·60, 95%
CI: 0·42 - 0·87) led to significantly lower recovery than
Prednisolone alone and this was not significantly differ-
ent compared with placebo (OR = 1·25, 95% CI: 0·78 -
1·98 for Placebo versus Acyclovir; OR = 0·91, 95% CI:
0·63 - 1·31 for Placebo versus Valacyclovir). These data
indicate that Prednisolone led to higher recovery rates
than not receiving Predisolone. We therefore combined
all Prednisolone groups (regardless of additional AVT)
compared with non-Prednisolone (i.e., Acyclovir, Valacy-
clovir, and Placebo). The estimated OR was 1·94 (95% CI:
1·55 - 2·42), i.e., Prednisolone-based treatment increase
the chance of recovery by 3 months by 2 fold compared
to non-Prednisolone-based treatment.
These effects were largely consistent when recovery
was judged at later time points (Figure 3b and table 3).
Acyclovir (OR = 1·74, 95% CI: 0·93 - 3·24) or Valacyclo-
vir (OR = 1·15, 95% CI: 0·78 - 1·69) added to Predniso-
lone tended to improve recovery rates compared
to receiving Prednisolone alone but the effects were
non-significant. Mono-therapy with either Acyclovir
(OR = 0·33, 95% CI: 0·18 - 0·68) or Valacyclovir (OR =
0·55, 95% CI: 0·37 - 0·81), or placebo (OR = 0·62, 95%
CI: 0·43 - 0·88) led to significantly lower recovery than
Prednisolone mono-therapy. Compared with Acyclovir,
Acyclovir or Valacyclovir plus Prednisolone was more
beneficial than Acyclovir alone, with ORs of 5·21 (95%
CI: 2·48 - 10·94) and 3·45 (95% CI: 1·78 - 6·68) respec-
tively; trends were similar for Valacyclovir. Overall, the
effect of prednisolone-based regimens compared
to those without prednisolone was similar to that at
3 months, with OR of 2·04 (95% CI 1·57 - 2·64).
Comparison of direct and network meta-analysis
Results of direct and network analyses are compared in
the last column of table 3. Direction of treatment effects
between both methods were similar for all comparisons,
although the direct approach provided higher treatment
effects in both positive and negative directions. The
degree of discrepancy between the 2 methods was very
small except for Acyclovir versus Prednisolone, where Z
was large and significant at 3 and 6 months (1·77, p =
0·077; and -2·93, p = 0·002 respectively). Precision of
treatment effects was generally higher in the network
meta-analysis than the direct one.
Finally, estimates of NNT and NNH for recovery at
3a n d6m o n t h sa r eg i v e ni nt a b l e4 .W ef o u n dt h a t
6 patients need to be treated with Acyclovir and predni-
solone compared to placebo in order to gain 1 extra
recovery and this had a tight confidence interval. By con-
trast, the benefit of combination AT and prednisolone
compared to prednisolone alone was less certain, with
26 patients needing to be treated with Acyclovir plus pre-
dinisolone in order to gain 1 extra patient with recovery
at 3 months, and this had wide confidence intervals.
Discussion
Our network meta-analysis indicates that treatment with
AVT alone or placebo is significantly inferior to Predni-
solone alone; the effect of AVT alone and placebo are
similar to each other. Current practice of adding AVT
(either Acyclovir or Valacyclovir) in the regimen with
Prednisolone may increase disease recovery rates com-
pared with Prednisolone alone, but at this point this dif-
ference is not statistically significant. Prednisolone
remains the strongest evidence-based treatment,
whether compared to placebo or AVT monotherapy.
The possible explanations for the lack of any incre-
mental effect of AVT when added to corticosteroids
might include:
￿ corticosteroids reduces the inflammatory process
in Bell’s palsy and this facilitates remyelination of
facial nerve.
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Page 6 of 10￿ Bell’s palsy is a post-infectious immune mediated
facial neuropathy rather than direct viral infection
￿ There may be a small incremental increase in effi-
cacy but there is not sufficient power, even with all
the trials to date, to demonstrate this. Large RCTs
are needed to specifically compare corticosteroid
and corticosteroid plus AVT.
This meta-analysis demonstrates well the advantage of
the network approach. Assessing the efficacy of treat-
ments for Bell’s palsy based on results of individual
RCTs and direct meta-analysis is difficult due to the fact
that there are various treatment regimens, and too few
studies performing the same treatment comparisons for
pooling. For instance, 6 treatment regimens are possible
prednisolone
n=567
1.02
(1 study) 1.24
(1 study)
With prednisolone
valacyclovir +
prednisolone
n=320
acyclovir +
prednisolone
n=206
valacyclovir
n=207
acyclovir
n=177
placebo
n=328
0.60*
(1 study) 0.44*
(1 study)
1.22
1.87*
(2 studies)
2.27*
(3 studies)
1.37
0.91 (1 study)
1.25
(2 studies)
OR=1.94
Without prednisolone
a) 3-month
prednisolone
n=537
1.15
(2 studies) 1.74
(3 studies)
With prednisolone
valacyclovir +
prednisolone
n=320
acyclovir +
prednisolone
n=221
valacyclovir
n=207
acyclovir
n=123
placebo
n=328
0.55
*
(1 study) 0.33
*
(1 study)
1.51
*
1.86
*
(2 studies)
2.83
*
(3 studies)
1.64
1.12 (1 study)
1.84
*
(1 study)
OR=2.04
Without prednisolone
*significance
b) >3-month
Figure 3 Comparisons of recovery rates between treatment groups: A network meta-analysis. a) at 3 months. b) at > 3 months.
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Page 7 of 10Table 3 Comparisons of treatment effects on disease recovery at 3 months between direct and network meta-analyses
Time at assessment Intervention Group Reference Group Direct meta-analysis Network meta-analysis Discrepancy
n OR 95% CI SE n OR 95% CI SE Z P value
3 month Acy + Pred Pred 409 1·39 0·52-3·75 0·32 773 1·24 0·79-1·94 0·28 0.27 0.788
Val + Pred Pred 637 1·17 0·75-1·81 0·22 887 1·02 0·73-1·42 0·17 0·49 0·621
Acy Pred 351 0·26 0·15-0·46 0·28 744 0·44 0·28-0·68 0·10 -1·77 0·077
Val Pred 417 0·64 0·43-0·95 0·21 774 0·60 0·42-0·87 0·11 0·27 0·785
Plac Pred 665 0·50 0·36-0·70 0·17 895 0·54 0·40-0·74 0·09 -0·40 0·689
Acy+Pred Acy 247 2·45 1·33 - 4·53 0·29 383 2·84 1·68 - 4·78 0·75 0·83 0·20
Val+Pred Acy - - - - 497 2·32 1·37 - 3·93 0·62 - -
Val Acy - - - - 384 1·37 0·79 - 2·37 0·38 - -
Plac Acy 245 1·14 0·65 - 1·98 0·27 505 1·25 0·78 - 1·98 0·29 -0·23 0·41
Acy+Pred Val - - - - 413 2·06 1·20 - 3·56 0·57
Val+Pred Val 413 1·55 1·02 - 2·35 0·20 527 1·69 1·16 - 2·48 0·33 -0·22 0·411
Plac Val 413 0·97 0·65 - 1·45 0·20 535 0·91 0·63 - 1·31 0·17 0·24 0·404
Acy+Pred Plac 246 2·16 1·17 - 4·00 0·29 534 2·27 1·31 - 2·66 0·55 -0·08 0·468
Val+Pred Plac 412 1·59 1·05 - 2·42 0·20 648 1·87 1·31 - 2·66 0·34 -0·41 0·340
Acy+Pred Val+Pred - - - - 526 1·22 0·72 - 2·06 0·32 - -
6 month Acy + Pred Pred 441 1·63 0·47 - 5·75 0·83 758 1·74 0·93-3·24 0·56 -0·07 0·474
Val + Pred Pred 637 1·58 0·55 - 4·48 0·40 857 1·15 0·78-1·69 0·23 0·67 0·246
Acy Pred 250 0·15 0·04 - 0·41 0·25 660 0·33 0·18-0·61 0·10 -2·93 0·002
Val Pred 417 0·55 0·36 - 0·85 0·21 744 0·55 0·37-0·81 0·11 0·00 0·500
Plac Pred 665 0·44 0·17 - 1·14 0·34 865 0·62 0·43-0·88 0·11 -0·96 0·169
Acy+Pred Acy 247 3·6 1·54 - 9·07 0·41 344 5·21 2·48 - 10·94 1·97 -0·18 0·427
Val+Pred Acy - - - - 443 3·45 1·78 - 6·68 1·16 - -
Val Acy - - - - 330 1·64 0·85 - 3·18 0·55 - -
Plac Acy 245 1·63 0. 80 - 3·34 0·34 451 1·84 1·02 - 3·33 0·56 -0·18 0·427
Acy+Pred Val - - - - 428 3·17 1·57 - 6·40 1·14
Val+Pred Val 413 1·89 1·23 - 2·92 0·21 527 2·10 1·40 - 3·15 0·44 -0·22 0·414
Plac Val 413 1·16 0·77 - 1·76 0·20 535 1·12 0·76 - 1·65 0·22 0·12 0·453
Acy+Pred Plac 246 2·21 0·89 - 5·82 0·43 549 2·83 1·46 - 5·47 0·95 -0·24 0·406
Val+Pred Plac 412 1·63 1·05 - 2·51 0·21 648 1·86 1·26 - 2·77 0·38 -0·30 0·381
Acy+Pred Val+Pred - - - - 541 1·51 0·75 - 3·05 0·54 - -
Table 4 Estimated numbers needed to treat and numbers needed to harm of treatments
Intervention Group Reference Group NNT/NNH (3 months) NNT/NNH (6 months)
Point Estimate 95% CI Point Estimate 95% CI
Acy + Pred Pred NNT 26 NNH 21 NNT 10 NNT 15 NNH 93 NNT 9
Val + Pred Pred NNT 271 NNH 16 NNT 17 NNT 52 NNH 26 NNT 16
Acy Pred NNH 6 NNH 3 NNH 13 NNH 5 NNH 3 NNH 12
Val Pred NNH 9 NNH 5 NNH 37 NNH 10 NNH 5 NNH 31
Plac Pred NNH 8 NNH 5 NNH 17 NNH 13 NNH 6 NNH 52
Acy+Pred Acy NNT 8 NNT 10 NNT 4 NNT 6 NNT 8 NNT 5
Val+Pred Acy NNT 3 NNT 15 NNT 5 NNT 7 NNT 12 NNT 6
Val Acy NNT 15 NNH 18 NNT 6 NNT 14 NNH 34 NNT 7
Plac Acy NNT 21 NNH 17 NNT 8 NNT 11 NNT 296 NNT 7
Acy+Pred Val NNT 6 NNT 22 NNT 4 NNT 4 NNT 10 NNT 3
Val+Pred Val NNT 8 NNT 27 NNT 5 NNT 6 NNT 13 NNT 4
Plac Val NNH 43 NNH 9 NNT 15 NNT 37 NNH 15 NNT 9
Acy+Pred Plac NNT 6 NNT 16 NNT 5 NNT 6 NNT 14 NNT 4
Val+Pred Plac NNT 7 NNT 16 NNT 5 NNT 9 NNT 22 NNT 6
Acy+Pred Val+Pred NNT 26 NNH 14 NNT 8 NNT 18 NNH 21 NNT 8
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Page 8 of 10in clinical practice (i.e., Acyclovir, Valacyclovir, Predni-
solone, Placebo, combination of Acyclovir + Predniso-
lone, and Valacyclovir + Prednisolone) resulting in
15 possible treatment-pair comparisons. Previous reviews
have had problems with this multiplicity of comparisons:
￿ a previous systematic review of AVT versus corti-
costeroid[7] included only 3 studies with 246
patients, and these could not be pooled since each
study had a different combination of treatments;
￿ one systematic review[34] included 3 studies with
117 patients and demonstrated no benefit of using
corticosteroid compared with placebo/vitamin with
relative risk of 0·86 (95% CI: 0·47 - 1·59).
￿ Another review[15] included 5 studies with 709 sam-
ples and reported no benefit of AVT (OR = 1·03; 95%
CI: 0·74 - 1·42) when compared with Prednisolone.
The small numbers in these previous meta-analyses
clearly led to lack of power. Two more complete
reviews[14,17] were recently published. One accessed
unpublished and non-English papers and thus included
more studies than other previous meta-analyses. Point
estimates of treatment effects for our results were simi-
lar to theirs, although confidence intervals varied. For
instance, the effect of corticosteroid versus placebo at
longer than 3 months was 0.54 in our study versus 0.69
for the recent meta but our study was slightly less pre-
cise (95% CIs were 0.40 - 0.74 versus 0.55 - 0.87, respec-
tively). Effect of AVT plus corticosteroid versus AVT
alone was also similar, i.e. the odds ratios for recovery
were 0.49 (95% CI: 0.36 - 0.66) versus 0.48 (95% CI:
0.29 - 0.79). Our results are also consistent with the
updated Cochrane review [17] which found a possibility
of benefit of AVT plus corticosteroid versus corticoster-
oid which did not reach statistical significance, with the
pooled point estimate of 1.41, and with the de Almeida
et al. review which also found borderline evidence for a
synergistic effect of steroids and AVT[14].
We have applied a mixed model for network meta-
analysis[19,31]. The mixed model gains power by inte-
grating both direct and indirect comparisons[15]. For
instance, only two studies performed direct comparisons
of Acyclovir plus Prednisolone versus Prednisolone
alone, a total sample size of 409 (Table 2). The network
method “borrowed” i n f o r m a t i o no nt h eP r e d n i s o l o n e
group from three other studies and increased the total
sample size to 773. Although our pooled estimates were
quite heterogeneous, the mixed model with random
intercept takes into account variation at the study level.
In addition, goodness of fit assessment suggested that
our model fit well with the data. Overall, our results are
quite robust since discrepancies between the direct and
the network analyses are small.
Quality of included studies varied; quality assessment
scores ranged from 2-12. Meta-regression of direct
meta-analysis indicated that this might be a source of
heterogeneity in pooling effects of AVT. However, we
could not adjust for the effects of quality assessment
score and other co-variables in the mixed effect model
since this requires individual patient data. An individual
patient data meta-analysis could be attempted, although
individual level raw data are often difficult and more
time consuming to access. However, with this method,
covariables in both study (e.g., quality assessment) and
individual levels (e.g., age, disease severity) can be
assessed using a multi-level analysis approach.
Conclusion
Our evidence suggests that the current practice of treat-
ing Bell’s palsy with AVT plus corticosteroid may lead
to slightly higher recovery rates at 3 and 6 months com-
pared to treating with corticosteroid alone, although at
this point the sum of the data do not show that this is a
significant difference; prednisone remains the best evi-
dence-based treatment. Treating with AVT alone is sig-
nificantly worse than treating with corticosteroid alone
and is no better than placebo.
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